Comparison of the clinical features and clinical course of antimitochondrial antibody‐positive and ‐negative primary biliary cirrhosis
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Reports from North America and Northern Europe have suggested that antimitochondrial antibody (AMA) negative primary biliary cirrhosis (PBC) is a distinct chronic cholestatic liver disease with high prevalence of serum non-organ-specific autoantibodies other than AMA. To evaluate if such a peculiar serum immunoreactivity is associated with clinically relevant characteristics, we reviewed our experience with 297 Italian patients who have had a clinical and histological diagnosis of PBC and were regularly followed-up at our Center from June 1974 to June 1994. AMA-negative and AMA-positive patients were compared in terms of biochemical and clinical features, and clinical outcome of the disease. At presentation, 30 of 297 patients (10%) tested negative for AMA by indirect immunofluorescence. Six of them tested positive for antimitochondrial M2 antibodies (AMA-M2) by immunoblotting analysis, therefore, diagnosis of AMA-negative PBC was made in 24 patients (8%). At the initial visit, AMA-negative and AMA-positive patients were similar in terms of biochemical and clinical features. Antinuclear and anti-smooth-muscle antibodies (ANA and ASMA) were more frequently positive in the AMA-negative patients (71% vs. 31%, and 37% vs. 9%; both P = .0002). Incidence of complications of cirrhosis and development of liver failure resulting in death or referral for liver transplantation did not differ significantly between the two populations. In conclusion, data from this historical cohort study suggest that the distinct serological features of AMA-negative PBC are not associated with substantial differences in the clinical spectrum or course of the disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although AMA-negative PBC patients are nearly identical to AMA-positive PBC patients, minor differences have been noted, including a higher prevalence of antinuclear and anti-smooth muscle antibodies and lower serum IgM levels.(111)(112)(113)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [113]
In the citing paper
“However, treatment response to UDCA appears similar in AMA-negative and AMA-positive PBC patients, and whether there are differences in clinical outcomes has not been resolved.(113,115)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [113]
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
Towbin, H., Staehelin, T., & Gordon, J. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.9.4350 · Cited by 53,385
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
Prognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816
(1959) · Postgraduate Medical Journal · doi:10.1136/pgmj.45.522.305-d · Cited by 497
Michieletti, P., Wanless, I. R., Katz, A., Scheuer, P. J., Yeaman, S. J., Bassendine, M. F., Palmer, J. M., & Heathcote, E. J. (1994) · Gut · doi:10.1136/gut.35.2.260 · Cited by 236
Autoimmune cholangiopathy: Part of the spectrum of autoimmune chronic active hepatitis
Ben-Ari, Z., Dhillon, A. P., & Sherlock, S. (1993) · Hepatology · doi:10.1002/hep.1840180103 · Cited by 218
Primary biliary cirrhosis: Paradigm or paradox for autoimmunity
Gershwin, M. E., & Mackay, I. R. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)80033-6 · Cited by 206
Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity
Lenzi, M., Ballardini, G., Bianchi, F. B., Johnson, P. J., McFarlane, I. G., Smith, H. M., McFarlane, B. M., Bridger, C., Williams, R., & Vergani, D. (1991) · The Lancet · doi:10.1016/0140-6736(91)90418-o · Cited by 200
Antimitochondrial antibody-negative primary biliary cirrhosis.
Lacerda, M. A., Ludwig, J., Dickson, E. R., Jorgensen, R. A., & Lindor, K. (1995) · PubMed · Cited by 196
Cited by
Alvarez, F., Berg, P. A., Bianchi, F. B., Bianchi, L., Burroughs, A. K., Cancado, E. L., Chapman, R. W., Cooksley, W. G. E., Czaja, A. J., Desmet, V. J., et al. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80297-9 · Cited by 2,903
(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
“(117-118) However, treatment response to UDCA appears similar in AMA-negative and AMA-positive PBC patients, and whether there are differences in clinical outcomes has not been resolved.(113,115)”
BackgroundResultChazouillères, O., Wendum, D., Serfaty, L., Montembault, S., Rosmorduc, O., & Poupon, R. (1998) · Hepatology · doi:10.1002/hep.510280203 · Cited by 746
Boberg, K. M., Chapman, R. W., Hirschfield, G. M., Lohse, A. W., Manns, M. P., & Schrumpf, E. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.09.002 · Cited by 555
“However, the majority view is that these patients have a variant of PBC, best regarded as AMA negative PBC [3,31,61,75–77].”
BackgroundInvernizzi, P., Podda, M., Battezzati, P. M., Crosignani, A., Zuin, M., Hitchman, E., Maggioni, M., Meroni, P. L., Penner, E., & Wesierska-Gadek, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(00)00040-4 · Cited by 455
Self-citationEpidemiology and natural history of primary biliary cirrhosis in a U.S. community
Kim, W. R., Lindor, K. D., Locke, G. R., Therneau, T. M., Homburger, H. A., Batts, K. P., Yawn, B. P., Petz, J. L., Melton, L. J., & Dickson, E. R. (2000) · Gastroenterology · doi:10.1053/gast.2000.20197 · Cited by 349
Selmi, C., Bowlus, C. L., Gershwin, M. E., & Coppel, R. L. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61965-4 · Cited by 334
Prevalence of autoimmune liver disease in Alaska natives
Hurlburt, K. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)04376-9 · Cited by 265
Lleo, A., Wang, G.-Q., Gershwin, M. E., & Hirschfield, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31607-x · Cited by 253
Diagnosis and Management of Primary Biliary Cholangitis
Younossi, Z. M., Bernstein, D., Shiffman, M. L., Kwo, P., Kim, W. R., Kowdley, K. V., & Jacobson, I. M. (2019) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0390-3 · Cited by 211
Apotopes and the biliary specificity of primary biliary cirrhosis†
Lleo, A., Selmi, C., Invernizzi, P., Podda, M., Coppel, R. L., Mackay, I. R., Gores, G. J., Ansari, A. A., Van de Water, J., & Gershwin, M. E. (2009) · Hepatology · doi:10.1002/hep.22736 · Cited by 222
“Second, the accessibility of PDC-E2 within apoptotic blebs to autoantibodies appears to support the pathogenic role of AMA as well as T cells in the perpetuation of BEC injury even though antibody titers do not correlate with the clinical features or stages of PBC, and AMA-negative patients are clinically indistinguis…”
BackgroundSelf-citationPrimary biliary cirrhosis once rare, now common in the United Kingdom?
James, O. F., Bhopal, R., Howel, D., Gray, J., Burt, A. D., & Metcalf, J. V. (1999) · Hepatology · doi:10.1002/hep.510300213 · Cited by 213
Autoimmune liver serology: Current diagnostic and clinical challenges
Bogdanos, D. P., Invernizzi, P., Mackay, I. R., & Vergani, D. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.3374 · Cited by 213
Self-citationThe Variant Forms of Autoimmune Hepatitis
Czaja, A. J. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00009 · Cited by 211
Neuberger, J. (1997) · The Lancet · doi:10.1016/s0140-6736(97)05419-6 · Cited by 179
Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis
Wesierska-Gadek, J., Penner, E., Battezzati, P. M., Selmi, C., Zuin, M., Hitchman, E., Worman, H. J., Gershwin, E. M., Podda, M., & Invernizzi, P. (2006) · Hepatology · doi:10.1002/hep.21172 · Cited by 177
Self-citationThe diagnosis of primary biliary cirrhosis
Bowlus, C. L., & Gershwin, M. E. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.041 · Cited by 162
Gastrointestinal Manifestations of Systemic Sclerosis
McFarlane, I. M., Bhamra, M. S., Kreps, A., Iqbal, S., Ani, F. A., Saladini‐Aponte, C., Grant, C., Singh, S., Awwal, K., Koci, K., et al. (2018) · Rheumatology Current Research · doi:10.4172/2161-1149.1000235 · Cited by 166
“AMA titers in PBC-alone cases do not necessarily correlate with disease severity or rate of progression [160,161].”
BackgroundPoupon, R. Y., Chazouillères, O., & Poupon, R. E. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80421-3 · Cited by 169
Trauner, & Graziadei (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00596.x · Cited by 151
Primary biliary cirrhosis and Sjögren’s syndrome: Autoimmune epithelitis
Selmi, C., Meroni, P. L., & Gershwin, M. E. (2012) · Journal of Autoimmunity · doi:10.1016/j.jaut.2011.11.005 · Cited by 145
“cholangitis” has been used for patients with PBC but lacking AMA but positive for serum antinuclear (ANA) and anti-smooth muscle (SMA) serum antibody [18,19].”
Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis†
Miozzo, M. R., Selmi, C. F., Gentilin, B., Grati, F. R., Sirchia, S. M., Oertelt‐Prigione, S., Zuin, M. G., Gershwin, M. E., Podda, M., & Invernizzi, P. (2007) · Hepatology · doi:10.1002/hep.21696 · Cited by 142
Self-citationYou, H., Ma, X., Efe, C., Wang, G., Jeong, S.-H., Abe, K., Duan, W., Chen, S., Kong, Y., Zhang, D., et al. (2022) · Hepatology International · doi:10.1007/s12072-021-10276-6 · Cited by 133
“Most studies suggested that the clinical presentation, liver histology and clinical course of AMA-negative PBC were nearly 1 3 identical to AMA-positive PBC [200, 201].”
Autoimmune cholangitis within the spectrum of autoimmune liver disease
Czaja, A. J., Carpenter, H. A., Santrach, P. J., & Moore, B. S. (2000) · Hepatology · doi:10.1053/jhep.2000.7878 · Cited by 136
“SMA and ANA $1:40 9 (45)f,j 80 (48) 3 (7)f 3 (10)j”
Invernizzi, P., Selmi, C., Poli, F., Frison, S., Floreani, A., Alvaro, D., Almasio, P., Rosina, F., Marzioni, M., Fabris, L., et al. (2008) · Hepatology · doi:10.1002/hep.22567 · Cited by 132
Self-citationPrimary biliary cirrhosis: Pathophysiology, clinical presentation and therapy
Purohit, T., & Cappell, M. S. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i7.926 · Cited by 138
Autoimmune liver disease: overlap and outliers
Washington, M. K. (2007) · Modern Pathology · doi:10.1038/modpathol.3800684 · Cited by 129
Variant forms of cholestatic diseases involving small bile ducts in adults
Kim, W. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)00791-7 · Cited by 119
Woodward, J. M., & Neuberger, J. (2001) · Hepatology · doi:10.1053/jhep.2001.23316 · Cited by 115
Interpreting serological tests in diagnosing autoimmune liver diseases
Invernizzi, P., Lleo, A., & Podda, M. (2007) · Seminars in Liver Disease · doi:10.1055/s-2007-979469 · Cited by 107
Self-citationPrimary biliary cirrhosis—presentation and diagnosis
Leuschner, U. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00101-6 · Cited by 106
Autoimmune hepatitis and its variant syndromes
BEN-ARI, Z., & CZAJA, A. J. (2001) · Gut · doi:10.1136/gut.49.4.589 · Cited by 102
Hendrickse, M. T., Rigney, E., Giaffer, M. H., Soomro, I. N., Triger, D. R., Underwood, J. C. E., & Gleeson, D. C. (1999) · Gastroenterology · doi:10.1053/gast.1999.0029900400 · Cited by 106
Antimitochondrial and other autoantibodies
Bogdanos, D. P., Baum, H., & Vergani, D. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00104-1 · Cited by 105
Identification of New Autoantigens for Primary Biliary Cirrhosis Using Human Proteome Microarrays
Hu, C.-J., Song, G., Huang, W., Liu, G.-Z., Deng, C.-W., Zeng, H.-P., Wang, L., Zhang, F.-C., Zhang, X., Jeong, J. S., et al. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.015529 · Cited by 96
Disease-specific autoantibodies in primary biliary cirrhosis
Bogdanos, D. P., & Komorowski, L. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.12.019 · Cited by 107
A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis
Agmon-Levin, N., Shapira, Y., Selmi, C., Barzilai, O., Ram, M., Szyper-Kravitz, M., Sella, S., Katz, B.-S. P., Youinou, P., Renaudineau, Y., et al. (2010) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.08.009 · Cited by 97
Self-citationShimoda, S., Miyakawa, H., Nakamura, M., Ishibashi, H., Kikuchi, K., Kita, H., Niiro, H., Arinobu, Y., Ono, N., Mackay, I. R., et al. (2008) · Journal of Autoimmunity · doi:10.1016/j.jaut.2008.05.003 · Cited by 92
Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers
Ritzel, U., Leonhardt, U., Näther, M., Schäfer, G., Armstrong, V. W., & Ramadori, G. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00006-5 · Cited by 94
Muratori, L., Granito, A., Muratori, P., Παππάς, Γ., & Bianchi, F. B. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.02.009 · Cited by 92
“From a clinical standpoint, however, the absence of AMA is almost irrelevant, because patients who have AMAnegative PBC have the same clinical, biochemical, and histologic features of classical (ie, AMA-positive) PBC [ 25 ,26], the same clinical outcomes, and the same biochemical response to ursodeoxycholic acid treat…”
BackgroundDiagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis
Czaja, A. J., Muratori, P., Muratori, L., Carpenter, H. A., & Bianchi, F. B. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.0924.x · Cited by 89
“Antinuclear antibodies 13 (87) 108 (72) pANCA 8 (53) 79 (52) Smooth muscle antibodies 10 (67) 112 (74) Anti-actin 9 (60) 74 (49) Anti-SLA/LP 2 (13) 12 (8) Anti-LKM1 0 (0) 2 (1) Anti-LC1 0 (0) 0 (0) AMA 0 (0) 5 (3) Anti-M2 0 (0) 6 (4) Anti-Sp100 2 (13) 8 (5) Anti-gp210 0 (0) 7 (5)”
Antimitochondrial Antibodies: from Bench to Bedside
Colapietro, F., Lleò, A., & Generali, E. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08904-y · Cited by 95
“Current literature has not evidenced any difference between the two groups concerning histology, clinical features, biochemistry, and response to UDCA [39].”
BackgroundInfluentialS2k Leitlinie Autoimmune Lebererkrankungen: AWMF-Reg. Nr. 021-27
Authors, Collaborators:, durch:, E. B., Deutsche Gesellschaft für Gastroenterologie, V. U. S. (. (., (DGIM), D. G. F. I. M., (DCCV), D. M. C. U. V., e.V., D. L., (DEGUM), D. G. F. U. I. D. M., (DGE-BV), D. G. F. E. U. B. V., (DGKJ), D. G. F. K. U. J., et al. (2017) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0043-120199 · Cited by 90
“[90] Invernizzi P, Crosignani A, Battezzati PM et al.”
BackgroundMURATORI, P., MURATORI, L., GERSHWIN, M. E., CZAJA, A. J., PAPPAS, G., MACCARIELLO, S., GRANITO, A., CASSANI, F., LORIA, P., LENZI, M., et al. (2003) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2004.02332.x · Cited by 86
Pbc and Ama—What Is the Connection?
Neuberger, J., & Thomson, R. (1999) · Hepatology · doi:10.1002/hep.510290126 · Cited by 86
GRANITO, A., MURATORI, P., MURATORI, L., PAPPAS, G., CASSANI, F., WORTHINGTON, J., GUIDI, M., FERRI, S., DE MOLO, C., LENZI, M., et al. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03172.x · Cited by 79
Barak, V., Selmi, C. F., Schlesinger, M., Blank, M., Agmon‐Levin, N., Kalickman, I., Gershwin, M. E., & Shoenfeld, Y. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.09.010 · Cited by 88
New ELISA for Detecting Primary Biliary Cirrhosis–Specific Antimitochondrial Antibodies
Dähnrich, C., Pares, A., Caballeria, L., Rosemann, A., Schlumberger, W., Probst, C., Mytilinaiou, M., Bogdanos, D., Vergani, D., Stöcker, W., et al. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.118299 · Cited by 76
Autoantibodies as Prognostic Markers in Autoimmune Liver Disease
Czaja, A. J. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-010-1268-4 · Cited by 83
“Furthermore, the conventional pathological autoantibodies of autoimmune hepatitis [33–35] and PBC [36, 37] are not required for the illness.”
Bizzaro, N., Covini, G., Rosina, F., Muratori, P., Tonutti, E., Villalta, D., Pesente, F., Alessio, M. G., Tampoia, M., Antico, A., et al. (2012) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-010-8234-y · Cited by 79
“mune cholangitis) as they appear to follow a similar natural history when compared to their AMA-positive counterparts [6].”
BackgroundMethodResultInfluentialSelf-citationPeculiar HLA polymorphisms in Italian patients with primary biliary cirrhosis
Invernizzi, P., Battezzati, P. M., Crosignani, A. L., Perego, F., Poli, F., Morabito, A., de Arias, A. E., Scalamogna, M., Zuin, M. G., & Podda, M. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00440-3 · Cited by 75
“Twenty-five patients (13%) who were AMA-negative but otherwise met the diagnostic criteria for PBC were considered as having AMA-negative PBC [16].”
BackgroundResultInfluentialSelf-citationUpdate on primary biliary cirrhosis
Invernizzi, P., Selmi, C. F., & Gershwin, M. E. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.02.014 · Cited by 74
“Although extremely useful as diagnostic marker, AMA are not clinically helpful during follow-up as several studies demonstrate that they do not correlate with stage (95).”
Self-citationB cell depletion therapy exacerbates murine primary biliary cirrhosis
Dhirapong, A., Lleo, A., Yang, G.-X., Tsuneyama, K., Dunn, R., Kehry, M., Packard, T. A., Cambier, J. C., Liu, F.-T., Lindor, K., et al. (2011) · Hepatology · doi:10.1002/hep.24044 · Cited by 70
Invernizzi, P., Battezzati, P. M., Crosignani, A., Zermiani, P., Bignotto, M., Del Papa, N., Zuin, M., & Podda, M. (2001) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.1998.00735.x · Cited by 70
Self-citationThe limitations and hidden gems of the epidemiology of primary biliary cirrhosis
Podda, M., Selmi, C. F., Lleò, A., Moroni, L., & Invernizzi, P. (2013) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.06.015 · Cited by 76
Self-citationAutoimmunity and Environment: Am I at risk?
Smyk, D. S., Rigopoulou, E. I., Baum, H., Burroughs, A. K., Vergani, D., & Bogdanos, D. P. (2011) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-011-8259-x · Cited by 73
Blood fetal microchimerism in primary biliary cirrhosis
Invernizzi, P., Andreis, C. D., Sirchia, S. M., Battezzati, P. M., Zuin, M. G., Rossella, F., Perego, F., Bignotto, M., Simoni, G., & Podda, M. (2000) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2000.01381.x · Cited by 69
Self-citationAutoimmune overlapping syndromes
Poupon, R. Y. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00092-8 · Cited by 73
“Except for the different autoantibody profiles (eg, they have high titer of ANA and SMA), the natural history, associated autoimmune conditions, and the response to UDCA therapy, in AMA positive and in AMA negative were virtually the same [47–53].”
ResultGatselis, N. K., Zachou, K., Norman, G. L., Gabeta, S., Papamichalis, P., Koukoulis, G. K., & Dalekos, G. N. (2013) · Autoimmunity · doi:10.3109/08916934.2013.801461 · Cited by 64
Hu, S., Zhao, F.-R., Wang, Q., & Chen, W. (2014) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2013-0926 · Cited by 67
Gordon, M. A., Oppenheim, E., Camp, N. J., di Giovine, F. S., Duff, G. W., & Gleeson, D. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80220-7 · Cited by 65
Experimental evidence on the immunopathogenesis of primary biliary cirrhosis
Selmi, C. F., Meda, F., Kasangian, A. A., Invernizzi, P., Tian, Z., Lian, Z., Podda, M., & Gershwin, M. E. (2009) · Cellular and Molecular Immunology · doi:10.1038/cmi.2009.104 · Cited by 64
Self-citationCholestatic phenotypes of autoimmune hepatitis
Czaja, A. J. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.08.039 · Cited by 63
“This latter category is probably heterogeneous and may include AMA-negative PBC and small duct PSC. (16, 17) In each cholestatic phenotype, AIH is the predominant disease.”
BackgroundBaldursdottir, T. R., Bergmann, O. M., Jonasson, J. G., Ludviksson, B. R., Axelsson, T. A., & Björnsson, E. S. (2012) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e328353753d · Cited by 62
Animal Models of Primary Biliary Cirrhosis
Katsumi, T., Tomita, K., Leung, P. S. C., Yang, G., Gershwin, M. E., & Ueno, Y. (2015) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8482-y · Cited by 62
Autoantibodies in Autoimmune Liver Disease
Czaja, A. J. (2005) · Advances in clinical chemistry · doi:10.1016/s0065-2423(05)40004-9 · Cited by 62
New insights to the immunopathology and autoimmune responses in primary biliary cirrhosis
He, X.-S., Ansari, A. A., Ridgway, W. M., Coppel, R. L., & Gershwin, M. E. (2006) · Cellular Immunology · doi:10.1016/j.cellimm.2006.04.006 · Cited by 59
Burak, K. W., Urbanski, S. J., & Swain, M. G. (2001) · Digestive Diseases and Sciences · doi:10.1023/a:1010620122567 · Cited by 61
“This has led to further confusion when defining AIC, as some authors have excluded patients who later test positive for AMA by immunoblotting (8, 9), although others have labeled patients as having AIC if the AMA is negative by immunofluorescence, even if the subsequent immunoblot is positive (12).”
BackgroundResultPredicting outcome in primary biliary cirrhosis
Lammers, W. J., Kowdley, K. V., & van Buuren, H. R. (2014) · Annals of Hepatology · doi:10.1016/s1665-2681(19)30838-5 · Cited by 59
“40,41 AMA subtypes were found to be associated with a progressive course in some studies, 42 but this was not confirmed by others.”
Breach of Tolerance: Primary Biliary Cirrhosis
Wang, L., Chang, C., Gershwin, M., & Wang, F.-S. (2014) · Seminars in Liver Disease · doi:10.1055/s-0034-1383729 · Cited by 56
Methotrexate for primary biliary cirrhosis
Giljaca, V., Poropat, G., Stimac, D., & Gluud, C. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004385.pub3 · Cited by 54
Beuers, U. H. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.11.009 · Cited by 61
“Since then, it became a matter of discussion whether PBC and AIC are separate entities [41,42] or variants of one single disease only differing in the pattern of associated autoantibodies [2,43–47].”
BackgroundPresence of antimitochondrial autoantibodies in patients with autoimmune hepatitis
Nezu, S., Tanaka, A., Yasui, H., Imamura, M., Nakajima, H., Ishida, H., & Takahashi, S. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04434.x · Cited by 52
Positive markers in AMA-negative PBC
Vergani, D., & Bogdanos, D. P. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07270.x · Cited by 52
“(8) reported a positive M2-specific band by immunoblotting in six of 25 (24%) PBC patients tested negative for AMA by immunofluorescence.”
Backgroundde Liso, F., Matinato, C., Ronchi, M., & Maiavacca, R. (2017) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2017-0249 · Cited by 54
The unfinished business of primary biliary cirrhosis
Selmi, C., Zuin, M., & Gershwin, M. E. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.06.006 · Cited by 50
“We believe this is too narrow as patients lacking serum AMA appear to follow a similar natural history when compared to their AMApositive counterparts [11].”
Self-citationAssessment of health related quality of life in polish patients with primary biliary cirrhosis
Raszeja-Wyszomirska, J., Wunsch, E., Krawczyk, M., Rigopoulou, E. I., Kostrzewa, K., Norman, G. L., Bogdanos, D. P., & Milkiewicz, P. (2016) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2015.10.006 · Cited by 47
Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis
Juliusson, G., Imam, M., Björnsson, E. S., Talwalkar, J. A., & Lindor, K. D. (2016) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2015.1132337 · Cited by 47
“Furthermore, they found no difference in biochemical response to UDCA.”
BackgroundInfluentialAntimitochondrial antibody‐negative primary biliary cirrhosis: a subset of primary biliary cirrhosis
Liu, B., Shi, X. H., Zhang, F. C., Zhang, W., & Gao, L. X. (2008) · Liver International · doi:10.1111/j.1478-3231.2007.01651.x · Cited by 49
“Antimitochondrial antibody -negative PBC patients have similar clinical courses and serum biochemical and hepatic histological features as AMA-positive ones (18, 19).”
BackgroundClinical features and management of primary biliary cirrhosis
Crosignani, A. L., Battezzati, P. M., Invernizzi, P., Selmi, C. F., Prina, E., & Podda, M. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.3313 · Cited by 51
Self-citationPRIMARY BILIARY CIRRHOSIS AND PRIMARY SCLEROSING CHOLANGITIS
Angulo, P., & Lindor, K. D. (1999) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70084-2 · Cited by 47
Antimitochondrial Antibody-Negative Primary Biliary Cirrhosis
Hirschfield, G. M., & Heathcote, E. J. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.02.003 · Cited by 46
Anti-nuclear envelope antibodies: Clinical associations
Nesher, G., Margalit, R. S., & Ashkenazi, Y. J. (2001) · Seminars in Arthritis and Rheumatism · doi:10.1053/sarh.2001.20266 · Cited by 48
Yamamoto, K., Terada, R., Okamoto, R., Hiasa, Y., Abe, M., Onji, M., & Tsuji, T. (2003) · Journal of Gastroenterology · doi:10.1007/s005350300006 · Cited by 44
Sakauchi, F., Mori, M., Zeniya, M., & Toda, G. (2006) · Journal of Epidemiology · doi:10.2188/jea.16.30 · Cited by 43
Contemporary epidemiology of primary biliary cholangitis
Colapietro, F., Bertazzoni, A., & Lleo, A. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.001 · Cited by 43
Neuberger, J. (2011) · Medicine · doi:10.1016/j.mpmed.2011.07.010 · Cited by 43
A Spectrum of Histopathologic Findings in Autoimmune Liver Disease
Terracciano, L., Patzina, R. A., Lehmann, F. S., Tornillo, L., Cathomas, G., Mhawech, P., Vecchione, R., & Bianchi, L. (2000) · American Journal of Clinical Pathology · doi:10.1309/bhym-hmy5-vm1p-7geg · Cited by 43
Liver biopsy in primary biliary cirrhosis: Clinicopathological data and stage
Drebber, U., Mueller, J. J. M., Klein, E., Kasper, H. U., Schulze, F., Schardt, K., Quasdorff, M., Schulte, S., Odenthal, M., & Dienes, H. P. (2009) · Pathology International · doi:10.1111/j.1440-1827.2009.02405.x · Cited by 42
SUZUKI, Y., ARASE, Y., IKEDA, K., SAITOH, S., TSUBOTA, A., SUZUKI, F., KOBAYASHI, M., AKUTA, N., SOMEYA, T., MIYAKAWA, Y., et al. (2004) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2004.03372.x · Cited by 40
Guidelines on the Diagnosis and Management of Primary Biliary Cholangitis (2021)
You, H., Duan, W., Li, S., Lv, T., Chen, S., Lu, L., Ma, X., Han, Y., Nan, Y., Xu, X., et al. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00347 · Cited by 45
Animal Models of Primary Biliary Cirrhosis
Chuang, Y., Ridgway, W. M., Ueno, Y., & Gershwin, M. E. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.02.011 · Cited by 39
Molecular diagnostic testing for primary biliary cholangitis
Gatselis, N., & Dalekos, G. N. (2016) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2016.1217159 · Cited by 42
AUTOANTIBODIES BY LINE IMMUNOASSAY IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS
Saito, H., Takahashi, A., Abe, K., Okai, K., Katsushima, F., Monoe, K., Kanno, Y., & Ohira, H. (2012) · FUKUSHIMA JOURNAL OF MEDICAL SCIENCE · doi:10.5387/fms.58.107 · Cited by 39
The diagnosis of antimitochondrial antibody-negative primary biliary cholangitis
Özaslan, E., Efe, C., & ÖZASLAN, N. G. (2016) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2016.06.001 · Cited by 39
Tanaka, A., Nezu, S., Uegaki, S., Mikami, M., Okuyama, S., KAWAMURA, N., Aiso, M., Gershwin, M. E., Takahashi, S., Selmi, C. F., et al. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1381.028 · Cited by 40
Czul, F., Peyton, A., & Levy, C. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.12.003 · Cited by 39
Advances in pharmacotherapy for primary biliary cirrhosis
Mousa, H. S., Lleò, A., Invernizzi, P., Bowlus, C. L., & Gershwin, M. E. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.998650 · Cited by 40
Self-citation
Metadata
- Authors
- Invernizzi, P., Crosignani, A., Battezzati, P. M., Covini, G., De Valle, G., Larghi, A., Zuin, M., & Podda, M.
- Affiliations
- Ospedale San Paolo (IT)
- Venue
- Hepatology
- Published
- 1997-05
- Volume
- 25
- Issue
- 5
- Pages
- 1090-1095
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1994218082
- Cited by
- 293
- References
- 18
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 4 · 2023: 5 · 2022: 5 · 2021: 7 · 2020: 7 · 2019: 4 · 2018: 7 · 2017: 8 · 2016: 5 · 2015: 10 · 2014: 11 · 2013: 6 · 2012: 18
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 6697 d)
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Keywords
- primary biliary cirrhosis, antimitochondrial antibodies, antinuclear antibodies, anti-smooth muscle antibodies, non-organ-specific autoantibodies, clinical course, cirrhosis complications, liver failure, liver transplantation, cholestatic liver disease
- MeSH terms
- Adult, Aged, Autoantibodies, Female, Humans, Liver Cirrhosis, Biliary, Male, Middle Aged, Mitochondria, Prognosis, Autoimmunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.